(PharmaNewsWire.Com, July 13, 2017 ) Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia. Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people.
Europe Hemophilia Management market is driven by factors such as growing prevalence of the haemophilia A and hemophilia B, increasing government support and increasing usage of recombinant products. Technological advancements along with rising investments in Research and developments for hemophilia products are also some of the key factors fuelling the growth of the market. However stringent regulatory policies, lack of available medication high cost of treatment are the major factors hindering the growth of the market. Advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide immense growth opportunities in the market.
Europe Hemophilia management market is segmented on the basis of type of hemophilia and type of drug. By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B. On the basis of drug type it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is projected to have the highest growth rate driven by large number of patients suffering from hemophilia A
Based on geography Europe hemophilia management market is analyzed under various regions namely United Kingdom, Germany, Italy, France and Spain. Europe is the second largest market for hemophilia management. Within Europe, United Kingdom is the largest market for hemophilia management accounting for a share of approximately XX% due to huge government support. Germany is estimated to be the fastest growing region with a highest CAGR of XX% owing to increasing disease burden.
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
